ArticleBMC cancer2026

Pretreatment clinical and hematological predictors of efficacy and immune-related adverse events in patients with advanced non-small cell lung cancer receiving first-line chemotherapy combined with immune checkpoint inhibitors.

Shun Matsuura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.